Roas 10 mg Pharmacom Labs

Roas 10 mg Pharmacom Labs: instructions for use

Roas 10 mg Pharmacom Labs is a retinoid. It is used medicinally to treat acne and sometimes as a treatment for certain types of cancer. It contains vitamin A and is used by athletes as a post-cycle therapy after taking anabolic steroids. The drug helps to eliminate side effects caused by steroids.

Main positive properties of Roas 10 mg Pharmacom Labs

The positive effect of this drug on the skin is known. Its main action:

• reduces sebum production;
• exhibits antimicrobial activity;
• reduces the size of sebaceous glands.

Thus, the remedy helps to eliminate acne, normalises sebum production and cleanses the skin. This is important after taking androgenic steroids, as their common side effect is acne, caused by increased activity of the sebaceous glands.

Possible side effects

The drug does not have a toxic effect, but may cause some side effects:

• temporary worsening of skin problems;
• reddening of the skin, dryness;
• nausea, abdominal pain, vomiting;
• dry lips and chapped lips.

As a rule, the symptoms disappear on their own within a short time. They have no long-term consequences and are not harmful to health.

Dosage and dosage rules

Be sure to consult your doctor before use. The medicine is prescribed when antibiotics and other strong medicines do not help to cope with the problem. There are contraindications, so the remedy cannot be used without a doctor’s permission.

As a general rule, start taking Roas 10 mg Pharmacom Labs once a day. The amount can be adjusted in both directions, depending on the individual characteristics of the organism. The course is long: 16-20 weeks.

List of references

1. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris–10 years later: a safe and successful treatment. Br J Dermatol. 1993;129(3):292-296.
2. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene Gel 0.3% for the Treatment of Acne Vulgaris: A Randomized, Controlled, Multicenter Study. J Am Acad Dermatol. 2006;54(2):242-250.
3. Lehucher-Ceyrac D, de la Salmonière P, Chastang C, Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology. 1999;198(3):278-283.
4. Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18(2):169-191.
5. Cunliffe WJ, Holland DB, Jeremy A. Comedone formation: etiology, clinical presentation, and treatment. Clin Dermatol. 2004;22(5):367-374.